Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: RCMac who wrote (7754)	1/17/2003 9:32:21 AM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Thanks, Bob. But of course those comments of mine about the non-risky nature of SEPR ICE's and MEDX/ABGX's antibody projects are looking a little less prescient now. <g> I guess I underestimated the market's reaction to one or two failures and the way that fed back into the development programs via the stock price, amplified by the general market decline. Basically there was a potential feedback loop that I missed. I still like these comments from the earlier part of that post though: Well there is certainly the hope that the timeline will compress some. But realistically, this is only going to effect the pre-clinical side much. We're still talking of the order of five years or more from entering the clinic to receiving approval. So I could see the overall timeline shortening from 10-12 years to say 8-10 years (perhaps a year or two less for some biologics), but that's still an awfully long time from a daytrader's perspective. <g>Note that I do believe trials will get cheaper and less risky as pharmacogenomics and a better understanding of fundamental biological processes give us a better window into just what a drug is doing. But I still don't think this will have a dramatic effect on timelines of clinical trials and approval. Of course for an individual biotech stock, the slow periods of little news are punctuated by exceedingly dramatic events (Fly-by-Genomics biotech is pleased to announce that it has regained all rights to ... <g>). Peter